Organization
Merck and Co., Inc.
3 abstracts
Abstract
A META-ANALYSIS OF ANALGESIC EFFICACY OF ROFECOXIB 50 MG FROM 13 CLINICAL STUDIESOrg: Clinical Research Centre, SCIREX Corporation, Austin Health, Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Merck and Co., Inc.,
Abstract
ANALYSIS OF THE ONSET OF EFFICACY WITH ROFECOXIB, CELECOXIB, AND ACETAMINOPHEN IN OSTEOARTHRITIS: THE VACT-2 TRIALOrg: Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Merck and Co., Inc., Arthritis Center of Nebraska, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
AN ECONOMIC COST ANALYSIS OF ETORICOXIB VERSUS INDOMETHACIN IN THE TREATMENT OF ACUTE GOUTY ARTHRITIS IN THE UKOrg: Innovus Research Inc., Merck and Co., Inc., Merck Research Laboratories, University of Leeds, Leeds General Infirmary,